Treatment with simvastatin in patients with impaired glucose tolerance and hypercholesterolemia reduced plasma levels of fibrinogen, FX:C, vWF:Ag, PAI-1, and FVII activity. This evidence concerns the gene RENBP and familial hypercholesterolemia.